Drug nanoparticles hitchhike on erythrocytes to target chemotherapy to the lungs for treating metastasis.

Suprachoroidal gene transfer with nonviral nanoparticles provides noninvasive transgene expression in photoreceptors and RPE.

Significance: Parkinson’s disease (PD) is a progressive disorder of the central nervous system that affects motor control. While subcutaneous injection of apomorphine (Apokyn) is clinically used to alleviate intermittent episodes of dyskinesia, the treatment requires multiple injections of the drug per day, significantly deterring patient compliance. We introduce a deep eutectic-based ternary solvent system that self-emulsifies in situ following subcutaneous injection and entraps apomorphine, allowing a 48-h duration of detectable drug concentration in the plasma of pigs, which is a remarkable improvement over the clinical comparator. The results from the animal studies support the self-emulsifying system as a potent, long-lasting therapeutic for PD patients and potentially for other therapeutics that have a similar delivery challenge.

Corneal transplantation remains a critical treatment option for individuals with corneal disorders, but it faces challenges such as rejection, high associated medical costs, and donor scarcity. A promising alternative for corneal replacement involves fabricating artificial cornea from a patient’s own cells. Our study aimed to leverage bioprinting to develop a corneal model using human corneal stromal cells embedded in a collagen-based bioink. We generated both cellular and acellular collagen I (COL I) constructs. Cellular constructs were cultured for up to 4 weeks, and gene expression analysis was performed to assess extracellular matrix (ECM) remodeling and fibrotic markers. Our results demonstrated a significant decrease in the expression of COL I, collagen III (COL III), vimentin (VIM), and vinculin (VCL), indicating a dynamic remodeling process towards a more physiologically relevant corneal ECM. Overall, our study provides a foundational framework for developing customizable, corneal replacements using bioprinting technology. Further research is necessary to optimize the bioink composition and evaluate the functional and biomechanical properties of these bioengineered corneas.

The cornea is a highly complex, transparent tissue, serving the critical role of focusing the light onto the retina. Due to global shortage of healthy donor corneas for transplantation, there is an urgent need for alternative strategies to restore corneal function in diseased or injured corneal cases. This demand has pushed researchers to develop synthetic tissue‐engineered corneas. In this context, three‐dimensional (3D) printing technologies have recently drawn significant attention due to their ability to fabricate complex, patient‐specific structures with various shapes and architectures, making them an interesting option for the fabrication of artificial corneal tissue. To date, numerous studies have focused on the fabrication and in vitro characterization of 3D‐printed corneal substitutes, but fewer of them have evaluated their therapeutic efficacy in vivo. This paper aims to provide a focused evaluation of the in vivo outcomes of synthetic corneal implants fabricated using various 3D‐printing techniques and materials. We also highlight current challenges and potential future directions for 3D printing of corneal substitutes.